Assembly Biosciences Q4 EPS $(1.74) Beats $(2.88) Estimate, Sales $7.16M
Portfolio Pulse from Benzinga Newsdesk
Assembly Biosciences (NASDAQ:ASMB) reported Q4 earnings with losses of $(1.74) per share, surpassing the $(2.88) consensus estimate. This marks a significant improvement from last year's $(5.52) per share loss. Sales reached $7.16 million for the quarter.
March 29, 2024 | 3:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Assembly Biosciences reported a narrower loss of $(1.74) per share in Q4, beating estimates and showing significant improvement from the previous year. Sales were $7.16 million.
The significant beat on both the EPS estimate and the improvement in losses year-over-year, combined with solid sales figures, are likely to be viewed positively by investors. This could lead to increased investor confidence and a potential short-term uptick in ASMB's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100